Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an important and growing class of oral medications used to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, patients frequently encountered in GI and endoscopy settings.
• Understanding that JAK3 signaling involves cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 helps explain why patients on these therapies may have altered immune responses, affecting infection risk during and after endoscopic procedures.
• Patients on JAK inhibitor therapy require careful pre-procedure screening for infection, medication timing considerations around colonoscopy/endoscopy, and clear documentation of current biologic/small-molecule regimens in the endoscopy unit's intake process.
• As this drug class expands beyond rheumatology into GI-specific indications, endoscopy nurses should expect increasing numbers of IBD patients presenting for surveillance or diagnostic procedures while on JAK-targeted therapy.

Clinical Relevance

This research summary highlights foundational science—the discovery of Jak3 and its role in cytokine signaling—that underlies a therapeutic class now firmly established in GI practice. While the original findings stemmed from immunodeficiency research (SCID), the resulting drug development pathway has produced JAK inhibitors that are FDA-approved for ulcerative colitis and are being studied for Crohn's disease. For endoscopy nurses, this means an increasing proportion of IBD patients arriving for colonoscopy, sigmoidoscopy, or capsule endoscopy may be on these agents, and nurses need working knowledge of their immunomodulatory effects.

From a practical standpoint, JAK inhibitors suppress signaling from multiple cytokines simultaneously, which can blunt the inflammatory response and mask early signs of infection or complications such as perforation. During pre-procedure assessments, nurses should ask targeted questions about JAK inhibitor use, recent infections, and any dose adjustments made by the gastroenterologist in anticipation of the procedure. Post-procedure, patients on these medications may require closer monitoring for delayed presentation of complications, since blunted cytokine signaling can dampen typical fever or pain responses that would otherwise alert clinical staff to problems like bowel perforation or bleeding.

This also has implications for patient education and unit protocols. Nurses are often the primary point of contact for reviewing medication lists, coordinating with prescribing gastroenterologists or rheumatologists about hold times before procedures, and educating patients on signs/symptoms to report at home. As more targeted immunomodulatory drugs enter GI practice—building on the same cytokine-signaling science described here—endoscopy units may need updated pre-procedure checklists and staff education modules specifically addressing JAK inhibitors, distinct from traditional biologics like anti-TNF agents.

Bottom Line

JAK inhibitors, developed from foundational cytokine signaling research, are increasingly used in IBD management, and GI nurses should be prepared to identify these medications during patient intake, understand their immune-suppressing effects, and maintain heightened vigilance for atypical or delayed signs of infection or procedural complications in this patient population.